Log In
BCIQ
Print this Print this
 

Subcutaneous Herceptin, trastuzumab

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionSubcutaneous formulation of humanized mAb against epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2; neu)
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentMarketed
Standard IndicationBreast cancer
Indication DetailsTreat HER2-positive breast cancer
Regulatory Designation EU - Standard Review (Treat HER2-positive breast cancer)
PartnerChugai Pharmaceutical Co. Ltd.;
Genentech Inc.;
Halozyme Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/17/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today